NOV 28, 2015 6:44 AM PST

Rare Tropical Disease Puts Transplant Patients At Risk

WRITTEN BY: Kara Marker
Leishmaniasis is an infectious disease caused by the bite of parasite-infected sand flies, and it's usually found in tropical regions and southern Europe. The infection can be either cutaneous, causing skin sores, or visceral, affecting internal organs (CDC). The number of leishmaniasis infections has quadrupled since the 1990s, and researchers from Spain looked to calculate the risk and determine how to prevent infections in vulnerable transplant patients. 
 Geographical distribution of visceral leishmaniasis

In a recent study published in PLoS Neglected Tropical Diseases, scientists looked at 63 individuals who had received solid organ transplants and worked to determine the number of patients who had come into contact with the parasite and what their risk was of developing leishmaniasis at any point for the rest of their lives. Because of the immunosuppressive therapy transplant patients receive to prevent organ rejection, these patients have a 100 times greater risk of developing severe visceral leishmaniasis compared to immunocompetent people.

The team conducted two tests scanning for any form of leishmaniasis infection. One test involved experimental lymphocyte proliferation assays and cytokine production analysis, to examine how the immune system was working, potentially hinting at a leishmaniasis invasion. The second test was more routine - "serologic and parasitology tests" that are normally used to diagnose cases of leishmaniasis. 

The scientists saw a correlation between the two tests, and this initial success points to the experimental assays as new indicators of leishmaniasis progression at various stages of infection. Continuing studies with these analytic tests could help scientists understand the relationship between transplant patients and their lifetime risk of developing leishmaniasis. 

Ultimately, the team is interested in preventing the initial transmission of leishmaniasis as well as relapse recovery. Identifying which immunocompromised patients are at high risk of relapsing with infection could help doctors know when to administer additional chemotherapeutics to prevent additional infections in individuals not completely recovered. 

"Being the recipient of an organ tranplant is increasingly common amoung the Spanish population," said Dr. Javier Moreno, team researcher. "As a consequence, it is necessary to both prevent the risk of infection in transplant patients and to adopt appropriate measures for disease management and prevention in clinical cases in order to prevent relapses."

Watch the following video to learn more about leishmaniasis. 

Source: Plataforma SINC
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 09, 2021
Immunology
A 'Plug-and-Play' CRISPR Therapy for Flu and COVID
MAR 09, 2021
A 'Plug-and-Play' CRISPR Therapy for Flu and COVID
Researchers have developed a CRISPR treatment that could potentially treat both viruses that cause COVID-19 and influenz ...
MAR 11, 2021
Immunology
Bye-Bye Burning: A New UTI Vaccine
MAR 11, 2021
Bye-Bye Burning: A New UTI Vaccine
Researchers have developed a vaccine that “trains” the bladder to fight back against the bacteria that cause ...
MAR 25, 2021
Immunology
The Immune System Impairs Antibiotic Effectiveness
MAR 25, 2021
The Immune System Impairs Antibiotic Effectiveness
Nitric oxide, a molecule produced by the immune system, can negatively impact antibiotics’ effectiveness, says a s ...
APR 16, 2021
Microbiology
A New Kind of COVID-19 Vaccine
APR 16, 2021
A New Kind of COVID-19 Vaccine
The current COVID-19 vaccines by Pfizer/BioNTech and Modern are based on messenger RNA, which cells use to make proteins ...
MAY 04, 2021
Immunology
One Vaccine to Rule Them All
MAY 04, 2021
One Vaccine to Rule Them All
There are currently five variants of concern in the U.S., genetically distinct forms of the COVID-causing coronavirus th ...
JUN 24, 2021
Immunology
Should We Rethink COVID Vaccine Recipes?
JUN 24, 2021
Should We Rethink COVID Vaccine Recipes?
In a study reported in the journal Cell, immunologists provide evidence for an Achilles’ heel in current COVI ...
Loading Comments...